Latent class analysis of ARDS subphenotypes: a secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) study

Intensive Care Medicine

Volumn 44, Issue 11, 2018, Pages 1859-1869

  Sinha, Pratik ^a   Delucchi, Kevin L ^b   Thompson, B Taylor ^c   McAuley, Daniel F ^d,e   Matthay, Michael A ^a,b   Calfee, Carolyn S ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^e ROYAL VICTORIA HOSPITAL   (United Kingdom)

Author keywords

ARDS; Latent class analysis; Statins; Subphenotypes

Indexed keywords

ALBUMIN; BICARBONATE; BILIRUBIN; C REACTIVE PROTEIN; CREATININE; HYPERTENSIVE FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN C; ROSUVASTATIN; SIMVASTATIN; TUMOR NECROSIS FACTOR RECEPTOR 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ALBUMIN BLOOD LEVEL; ARTICLE; BICARBONATE BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; HUMAN; LATENT CLASS ANALYSIS; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT RESPONSE; ACUTE LUNG INJURY; ADULT; AGED; COHORT ANALYSIS; COMPLICATION; FEMALE; MALE; MIDDLE AGED; SURVIVAL RATE;

ACUTE LUNG INJURY; ADULT; AGED; COHORT STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LATENT CLASS ANALYSIS; MALE; MIDDLE AGED; RESPIRATORY DISTRESS SYNDROME, ADULT; ROSUVASTATIN CALCIUM; SEPSIS; SURVIVAL RATE;

EID: 85054576180     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-018-5378-3     Document Type: Article

References (41)

1. Frank AJ, Thompson BT (2010) Pharmacological treatments for acute respiratory distress syndrome. Curr Opin Crit Care 16:62–68
2. Bosma KJ, Taneja R, Lewis JF (2010) Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: current and experimental approaches. Drugs 70:1255–1282
3. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, Garcia JG (2005) Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288:L1026–L1032
4. Chopra V, Rogers MA, Buist M, Govindan S, Lindenauer PK, Saint S, Flanders SA (2012) Is statin use associated with reduced mortality after pneumonia? A systematic review and meta-analysis. Am J Med 125:1111–1123
5. Shyamsundar M, McKeown ST, O’Kane CM, Craig TR, Brown V, Thickett DR, Matthay MA, Taggart CC, Backman JT, Elborn JS, McAuley DF (2009) Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med 179:1107–1114
6. McAuley DF, Laffey JG, O’Kane CM, Perkins GD, Mullan B, Trinder TJ, Johnston P, Hopkins PA, Johnston AJ, McDowell C, McNally C, HARP-2 Investigators, Irish Critical Care Trials Group (2014) Simvastatin in the acute respiratory distress syndrome. N Engl J Med 371:1695–1703
7. National Heart, Lung, and Blood Institute ARDS Clinical Trials Network, Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, Brower RG, Shanholtz C, Rock P, Douglas IS, deBoisblanc BP, Hough CL, Hite RD, Thompson BT (2014) Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med 370:2191–2200
8. Calfee CS, Delucchi K, Famous KR (2017) Reply: next step to understanding subphenotypes of acute respiratory distress syndrome. Am J Respir Crit Care Med 196:796
9. Famous KR, Delucchi K, Ware LB, Kangelaris KN, Liu KD, Thompson BT, Calfee CS, Network A (2017) Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 195:331–338
10. Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O’Kane CM, McAuley DF, Irish Critical Care Trials Group (2018) Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 6:691–698
11. Delucchi K, Famous KR, Ware LB, Parsons PE, Thompson BT, Calfee CS, ARDS Network (2018) Stability of ARDS subphenotypes over time in two randomised controlled trials. Thorax 73:439–445
12. Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA, NHLBI ARDS Network (2014) Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2:611–620
13. Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O’Kane CM, McAuley DF (2018) ARDS subphenotypes and differential response to simvastatin: secondary analysis of a randomized controlled trial. Lancet Respir Med 6:691–698
14. Sinha P, Delucchi K, Thompson BT, McAuley DF, Matthay MA, Calfee CS (2018) Latent class analysis of acute respiratory distress syndrome (ARDS): secondary analysis of the statins for acutely injured lungs from sepsis (SAILS) trial. Am J Respir Crit Care Med 197:A6187
15. Muthén LK, Muthén BO (2017) Mplus user’s guide (version 8). Muthen & Muthen, Los Angeles
16. Pierrakos C, Vincent JL (2012) The changing pattern of acute respiratory distress syndrome over time: a comparison of two periods. Eur Respir J 40:589–595
17. Wurpts IC, Geiser C (2014) Is adding more indicators to a latent class analysis beneficial or detrimental? Results of a Monte-Carlo study. Front Psychol 5:920
18. Maiolo G, Collino F, Vasques F, Rapetti F, Tonetti T, Romitti F, Cressoni M, Chiumello D, Moerer O, Herrmann P, Friede T, Quintel M, Gattinoni L (2018) Reclassifying acute respiratory distress syndrome. Am J Respir Crit Care Med 197:1586–1595
19. Nuckton TJ, Alonso JA, Kallet RH, Daniel BM, Pittet JF, Eisner MD, Matthay MA (2002) Pulmonary dead-space fraction as a risk factor for death in the acute respiratory distress syndrome. N Engl J Med 346:1281–1286
20. Warren MA, Zhao Z, Koyama T, Bastarache JA, Shaver CM, Semler MW, Rice TW, Matthay MA, Calfee CS, Ware LB (2018) Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. Thorax 73:840–846
21. Landesberg G, Levin PD, Gilon D, Goodman S, Georgieva M, Weissman C, Jaffe AS, Sprung CL, Barak V (2015) Myocardial dysfunction in severe sepsis and septic shock: no correlation with inflammatory cytokines in real-life clinical setting. Chest 148:93–102
22. Prescott HC, Calfee CS, Thompson BT, Angus DC, Liu VX (2016) Toward smarter lumping and smarter splitting: rethinking strategies for sepsis and acute respiratory distress syndrome clinical trial design. Am J Respir Crit Care Med 194:147–155
23. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, Rautanen A, Gordon AC, Garrard C, Hill AV, Hinds CJ, Knight JC (2016) Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. Lancet Respir Med 4:259–271
24. Sweeney TE, Azad TD, Donato M, Haynes WA, Perumal TM, Henao R, Bermejo-Martin JF, Almansa R, Tamayo E, Howrylak JA, Choi A, Parnell GP, Tang B, Nichols M, Woods CW, Ginsburg GS, Kingsmore SF, Omberg L, Mangravite LM, Wong HR, Tsalik EL, Langley RJ, Khatri P (2018) Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med 46:915–925
25. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, Nurnberg P, Schultz MJ, Horn J, Cremer OL, Bonten MJ, Hinds CJ, Wong HR, Knight JC, van der Poll T, MARS consortium (2017) Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. Lancet Respir Med 5:816–826
26. Wong HR, Cvijanovich N, Lin R, Allen GL, Thomas NJ, Willson DF, Freishtat RJ, Anas N, Meyer K, Checchia PA, Monaco M, Odom K, Shanley TP (2009) Identification of pediatric septic shock subclasses based on genome-wide expression profiling. BMC Med 7:34
27. Siempos II, Maniatis NA, Kopterides P, Magkou C, Glynos C, Roussos C, Armaganidis A (2010) Pretreatment with atorvastatin attenuates lung injury caused by high-stretch mechanical ventilation in an isolated rabbit lung model. Crit Care Med 38:1321–1328
28. Craig TR, Duffy MJ, Shyamsundar M, McDowell C, O’Kane CM, Elborn JS, McAuley DF (2011) A randomized clinical trial of hydroxymethylglutaryl-coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med 183:620–626
29. Sahebkar A, Rathouska J, Simental-Mendia LE, Nachtigal P (2016) Statin therapy and plasma cortisol concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res 103:17–25
30. Sahebkar A, Serban C, Ursoniu S, Mikhailidis DP, Undas A, Lip GY, Bittner V, Ray K, Watts GF, Hovingh GK, Rysz J, Kastelein JJ, Banach M, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group (2016) The impact of statin therapy on plasma levels of von Willebrand factor antigen. Systematic review and meta-analysis of randomised placebo-controlled trials. Thromb Haemost 115:520–532
31. Bonsu KO, Reidpath DD, Kadirvelu A (2015) Effects of statin treatment on inflammation and cardiac function in heart failure: an adjusted indirect comparison meta-analysis of randomized trials. Cardiovasc Ther 33:338–346
32. Smith MEB, Lee NJ, Haney E, Carson S (2009) Drug class review: HMG-CoA reductase inhibitors (statins) and fixed-dose combination products containing a statin: final report update 5. Oregon Health & Science University, Portland
33. Lee CC, Lee MG, Hsu TC, Porta L, Chang SS, Yo CH, Tsai KC, Lee M (2018) A population-based cohort study on the drug-specific effect of statins on sepsis outcome. Chest 153:805–815
34. Mansur A, Steinau M, Popov AF, Ghadimi M, Beissbarth T, Bauer M, Hinz J (2015) Impact of statin therapy on mortality in patients with sepsis-associated acute respiratory distress syndrome (ARDS) depends on ARDS severity: a prospective observational cohort study. BMC Med 13:128
35. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, Vincent JL (2003) C-reactive protein levels correlate with mortality and organ failure in critically ill patients. Chest 123:2043–2049
36. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R, Heinrich PC (1990) Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12:1179–1186
37. Bajwa EK, Khan UA, Januzzi JL, Gong MN, Thompson BT, Christiani DC (2009) Plasma C-reactive protein levels are associated with improved outcome in ARDS. Chest 136:471–480
38. Pierrakos C, Vincent JL (2010) Sepsis biomarkers: a review. Crit Care 14:R15
39. Navarro SL, Kantor ED, Song X, Milne GL, Lampe JW, Kratz M, White E (2016) Factors associated with multiple biomarkers of systemic inflammation. Cancer Epidemiol Biomarkers Prev 25:521–531
40. Mackenzie I, Woodhouse J (2006) C-reactive protein concentrations during bacteraemia: a comparison between patients with and without liver dysfunction. Intensive Care Med 32:1344–1351
41. Bos LD, Schouten LR, van Vught LA, Wiewel MA, Ong DSY, Cremer O, Artigas A, Martin-Loeches I, Hoogendijk AJ, van der Poll T, Horn J, Juffermans N, Calfee CS, Schultz MJ, Consortium M (2017) Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax 72:876–883